The deal range was $22.00-$23.00. Jefferies, Leerink, Evercore ISI and Stifel acted as joint book running managers for the offering.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Viridian Therapeutics announces common stock and preferred stock offering
- Viridian Therapeutics price target raised to $36 from $32 at Oppenheimer
- 3 Best Stocks to Buy Now, 10/21/2025, According to Top Analysts
- Viridian Therapeutics Secures $300M Deal with DRI Healthcare
- Viridian Therapeutics: Strategic Financial Agreement and Promising Product Launches Drive Buy Rating